Matches in SemOpenAlex for { <https://semopenalex.org/work/W4252256930> ?p ?o ?g. }
Showing items 1 to 56 of
56
with 100 items per page.
- W4252256930 endingPage "i" @default.
- W4252256930 startingPage "i" @default.
- W4252256930 abstract "It has been recommended that modern equine influenza vaccines should contain an A/equi-1 strain and A/equi-2 strains of the American and European-like subtype. We describe here the efficacy of a modern updated inactivated equine influenza-herpesvirus combination vaccine against challenge with a recent American-like isolate of equine influenza (A/equine-2/Kentucky/95 (H3N8). The vaccine contains inactivated Influenza strains A-equine-1/Prague’56, A-equine-2/Newmarket-1/’93 (American lineage) and A-equine-2/ Newmarket-2/93 (Eurasian lineage) and inactivated EHV-1 strain RacH and EHV-4 strain V2252. It is adjuvanted with alhydrogel and an immunostim. Horses were vaccinated at the start of the study and 4 weeks later. Four, six and eight weeks after the first vaccination high anti-influenza antibody titres were found in vaccinated horses, whereas at the start of the study all horses were seronegative. After the challenge, carried out at 8 weeks after the first vaccination, nasal swabs were taken, rectal temperatures were measured and clinical signs were monitored for 14 days. In contrast to unvaccinated control horses, vaccinated animals shed hardly any virus after challenge, and the appearance of clinical signs of influenza such as nasal discharge, coughing and fever were reduced in the vaccinated animals. Based on these observations, it was concluded that the vaccine protected against clinical signs of influenza and, more importantly, against virus excretion induced by an American-like challenge virus strain. In a second experiment the duration of the immunity induced by this vaccine was assessed serologically. Horses were vaccinated at the start of the study and 6 and 32 weeks later. Anti-influenza antibody titres were determined in bloodsamples taken at the first vaccination, and 2, 6, 8, 14, 19, 28, 32, 37, 41, 45 and 58 weeks after the first vaccination. Vaccinated horses had high anti-influenza antibody titres, above the level for clinical protection against influenza, against all strains present in the vaccine until 26 weeks after the third vaccination." @default.
- W4252256930 created "2022-05-12" @default.
- W4252256930 date "2004-03-01" @default.
- W4252256930 modified "2023-09-27" @default.
- W4252256930 title "Editorial board" @default.
- W4252256930 doi "https://doi.org/10.1016/s1090-0233(04)00024-3" @default.
- W4252256930 hasPublicationYear "2004" @default.
- W4252256930 type Work @default.
- W4252256930 citedByCount "0" @default.
- W4252256930 crossrefType "other" @default.
- W4252256930 hasConcept C126322002 @default.
- W4252256930 hasConcept C151730666 @default.
- W4252256930 hasConcept C159047783 @default.
- W4252256930 hasConcept C203014093 @default.
- W4252256930 hasConcept C22070199 @default.
- W4252256930 hasConcept C2522874641 @default.
- W4252256930 hasConcept C2778022156 @default.
- W4252256930 hasConcept C2778022620 @default.
- W4252256930 hasConcept C2779341262 @default.
- W4252256930 hasConcept C2780762169 @default.
- W4252256930 hasConcept C71924100 @default.
- W4252256930 hasConcept C86803240 @default.
- W4252256930 hasConcept C8891405 @default.
- W4252256930 hasConceptScore W4252256930C126322002 @default.
- W4252256930 hasConceptScore W4252256930C151730666 @default.
- W4252256930 hasConceptScore W4252256930C159047783 @default.
- W4252256930 hasConceptScore W4252256930C203014093 @default.
- W4252256930 hasConceptScore W4252256930C22070199 @default.
- W4252256930 hasConceptScore W4252256930C2522874641 @default.
- W4252256930 hasConceptScore W4252256930C2778022156 @default.
- W4252256930 hasConceptScore W4252256930C2778022620 @default.
- W4252256930 hasConceptScore W4252256930C2779341262 @default.
- W4252256930 hasConceptScore W4252256930C2780762169 @default.
- W4252256930 hasConceptScore W4252256930C71924100 @default.
- W4252256930 hasConceptScore W4252256930C86803240 @default.
- W4252256930 hasConceptScore W4252256930C8891405 @default.
- W4252256930 hasIssue "2" @default.
- W4252256930 hasLocation W42522569301 @default.
- W4252256930 hasOpenAccess W4252256930 @default.
- W4252256930 hasPrimaryLocation W42522569301 @default.
- W4252256930 hasRelatedWork W124972543 @default.
- W4252256930 hasRelatedWork W1963962441 @default.
- W4252256930 hasRelatedWork W1977527856 @default.
- W4252256930 hasRelatedWork W2015148815 @default.
- W4252256930 hasRelatedWork W2098074649 @default.
- W4252256930 hasRelatedWork W2161192147 @default.
- W4252256930 hasRelatedWork W2416178960 @default.
- W4252256930 hasRelatedWork W2773781609 @default.
- W4252256930 hasRelatedWork W2973639028 @default.
- W4252256930 hasRelatedWork W3025837618 @default.
- W4252256930 hasVolume "167" @default.
- W4252256930 isParatext "true" @default.
- W4252256930 isRetracted "false" @default.
- W4252256930 workType "paratext" @default.